Interferon-α-n1. A review of its pharmacological properties and therapeutic efficacy in the management of chronic viral hepatitis

BioDrugs

Volumn 9, Issue 2, 1998, Pages 125-154

  Perry, Caroline M ^a   Wagstaff, Antona J ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHAN1 INTERFERON; ANTIVIRUS AGENT; CORTICOSTEROID; DEFLAZACORT; HEPATITIS B(E) ANTIGEN; LEVAMISOLE; NEUTRALIZING ANTIBODY; PARACETAMOL; PREDNISOLONE; PREDNISONE; RECOMBINANT ALPHA INTERFERON; VIRUS DNA; ZIDOVUDINE;

ADVERSE DRUG REACTION; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL ACTIVITY; ARTHRALGIA; AUTOIMMUNE DISEASE; CHILL; CLINICAL TRIAL; DEPRESSION; DRUG ADMINISTRATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG TOLERABILITY; FATIGUE; FEVER; FLU LIKE SYNDROME; HEADACHE; HEPATITIS B; HEPATITIS C; HUMAN; IMMUNOMODULATION; INTRAMUSCULAR DRUG ADMINISTRATION; LIVER CELL CARCINOMA; LYMPHOBLASTOID CELL; MYALGIA; NEUTROPENIA; PHARMACODYNAMICS; PRIORITY JOURNAL; PRURITUS; REVIEW; SEIZURE; SENDAI VIRUS; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTOPENIA; THYROID DISEASE; VIRUS HEPATITIS;

EID: 0031913056     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-199809020-00004     Document Type: Review

References (144)

1. Cirelli R, Tyring SK. Major therapeutic uses of interferons. Clin Imminother 1995; 3(1): 27-87
2. Dianzani F. Biological basis for the clinical use of interferon. Gut 1993: S74-6
3. Farrell GC. Therapy of hepatitis C: Interferon alfa-nl trials. Hepatology 1997; 26 Suppl. 1: 96S-100S
4. Dorr RT. Interferon-α in malignant and viral diseases: a review. Drugs 1993; 45 (2): 177-211
5. Wellcome UK. Wellferon. Interferon alfa-nl. Prescribing information. ABPI Compendium of Data Sheets and Summaries of Product Characteristics 1996-7. Datapharm Publications Limited. London, UK
6. Davis MG, Jansen RW. Inhibition of hepatitis B virus in tissue culture by alpha interteron. Antimicrob Agents Chemother 1994 Dec; 38: 2921-4
7. Staehcli P. Interferon-induced proteins and the antiviral state. Adv Virus Res 1990; 38: 147-200
8. Nouri-Aria KT, Alexander GJM, Magrin S, et al. Differential effect of α-interferons on CD4- and CD8-positive lymphocytes in chronic hepatitis B virus carriers. J Hepatol 1988; 7 (1): 1-6
9. Lucas M, Serejo F, Valente A, et al. Changes in peripheral blood lymphocyte subsets in chronic hepatitis C: differences between α-2b and α-nl interferon [abstract]. Hepatology 1993 Oct; 18(Pt 2): 241A
10. Custilla A, Camps Bansell-J, Civeira M-P, et al. Lymphoblastoid α-interferon for chronic hepatitis C: a randomized controlled study. Am J Gastroenterol 1993; 88 (2): 233-9
11. Dunk AA, Ikeda T, Pignatelli M, et al. Human lymphoblastoid interferon. In vitro and in vivo studies in hepatocellular carcinoma. J Hepatol 1986; 2 (3): 419-29
12. Dunk AA, Novick D, Thomas HC. Natural killer cell activity in hepatocellular carcinoma. In vitro and in vivo responses to interferon. Scand J Gastroenterol 1987; 22 (10): 1245-50
13. Andreone P, Cursaro C, Gasbarrini G. Interferon-α increases prostaglandin E2 production by cultured liver biopsy in patients with chronic viral hepatitis: can non-steroidal anti-inflammatory drugs improve the therapeutic response to interferon? J Hepatol 1993; 19(2): 228-31
14. Huber BE, Wirth PJ, Newbold JE. Effects of human lymphoblastoid interferon on proliferation, gene expression and tumourigenicity of human hepatoma cell lines. Drugs Exp Clin Res 1991; 17: 281-91
15. Dianzani F, Antonelli G, Currenti M, et al. Induction of neutralizing antibodies to interferon during treatment of hepatitis patients: comparison among different interferon preparations [abstract]. Antiviral Res 1991 Apr; 15 Suppl. 1: 127
16. Brand CM, Leadbeater L. Specificities of therapy-induced antiinterferon-α antibodies. J Interferon Res 1994 Aug; 14: 201-3
17. Antonelli G, Currenti M, Turriziani O, et al. Neutralizing antibodies to interferon-α: relative frequency in patients treated with different interferon preparations. J Infect Dis 1991 Apr; 163: 882-5
18. Brand CM, Leadbeater L, Bellati G, et al. Antibodies developing against a single recombinant interferon protein may neutralize many other interferon-α subtypes. J Interferon Res 1993 Apr; 13: 121-5
19. Dianzani F, Baron S. Medical microbiology, 3rd ed. New York: Churchill Livingstone, 1991
20. Samuel CE. Mechanisms of the antiviral action of the interferons. Prog Nucleic Acid Res Mol Biol 1988; 35: 27-72
21. Caselmann WH, Meyer M, Scholz S, et al. Type 1 interferons inhibit hepatitis B virus replication and induce hepatocellular gene expression in cultured liver cels. J Infect Dis 1992; 166: 966-71
22. Samuel CE. Antiviral actions of interferon. Interferon-regulated cellular proteins and their surprisingly selective antiviral activities. Virology 1991; 183: 1-11
23. Thomas NSB, Linch DC. An intracellular 50-kDa Fcγ-binding protein is induced in human cells by α-IFN. J Immunol 1991 ; 146(5): 1649-54
24. Hannigan GE, Williams BRG. Signal transduction by interferon-α through arachidonic metabolism. Science 1991; 251: 204-7
25. Andreone P, Cursaro C, Gramenzi A, et al. Indomethacin increases 2',5'-oligoadenylate synthetase release by cultured liver tissue of patients with HCV chronic active hepatitis. Int Hepatol Commun 1994; 2(5): 289-94
26. Edman JC, Gray P, Vulenzuela P, et al. Integration of hepatitis B virus sequences and their expression in a human hepatoma cell. Nature 1980 Jul 31; 286: 535-8
27. Popper H. The relation between hepatitis B virus infection and hepatocellular carcinoma. Hepatogastroenterology 1986; 33: 2-5
28. Chuang W-L. Chang W-Y. Lu S-N. et al. The role of hepatitis B and C viruses in hepatocellular carcinoma in a hepatitis B endemic area. A case-control study. Cancer 1992; 69: 2052-4
29. Colombo M, Choo QL, Del Ninno E. et al. Prevalence of antibody to hepatitis C virus in Italian patients with hepatocellular carcinoma. Lancet 1989; II: 1006-8
30. Simonetti RG, Cammá C, Fiorello F, et al. Hepatitis C virus infection as a risk factor for hepatocellulr carcinoma in patients with cirrhosis. A case-control study. Ann Intern Med 1992; 2: 97-102
31. Mazzella G, Accogli E, Sottili S, et al. Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis. J Hepatol 1996; 24 (2): 141-7
32. Liaw Y-F. Current therapeutic trends for chronic viral hepatitis. J Gastroenterol Hepatol 1997; 12: S346-53
33. Oon J-C. Tan N, Lim GK. Natural lymphoblastoid Wellferon in the prevention of hepatocellular carcinoma in high-risk (HBsAg) positive carriers: A 5-year follow-up [abstract]. IXth Triennial International Symposium on viral hepatitis and liver disease; 1996 Apr 21-25; Rome. B32
34. Oon J-C. Long-term survival following treatment of hepatocellular carcinoma in Singapore: evaluation of Wellferon in the prophylaxis of high-risk pre-cancerous conditions. Cancer Chemother Pharmacol 1992;31 Suppl.: S137-142
35. Shafritz DA, Shouval D, Sherman HI, et al. Integration of hepatitis B virus DNA into the genome of liver cells in chronic liver disease and hepatocellular carcinoma. N Engl J Med 1981; 305 (18): 1067-73
36. Nishiguchi S, Kuroki T, Nakatani S, et al. Randomised trial of effects of interferon-α on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995 Oct 21; 346: 1051-5
37. Bellentani S, Tiribelli C, Saccoccio G, et al. Prevalence of chronic liver disease in the general population of Northern Italy: The Dionysos Study. Hepatology 1994; 20: 1442-9
38. Antonelli G. Giannelli G, Currenti M, et al. Antibodies to interferon (IFN) in hepatitis C patients relapsing while continuing recombinant IFN-α2 therapy. Clin Exp Immunol 1996; 104: 384-7
39. Wong S, Gauthier T, Kaita KDE, et al. The differential effects of three forms of interferon alfa on hepatic regeneration after partial hepatectomy in the rat. Hepalology 1995 Sep: 22: 883-6
40. Hoofnagle JH, Di BAM. The treatment of chronic viral hepatitis. N Engl J Med 1997 Jan 30; 336: 347-56
41. Desmet V, Gerber M. Hoofnagle JH, et al. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994; 19: 1513-20
42. Woo MH, Burnakis TG. Interferon alfa in the treatment of chronic viral hepatitis B and C. Ann Pharmacother 1997 Mar; 31 (3): 330-7
43. Liaw Y-F, Lin S-M, Chen T-J, et al. Beneficial effect of prednisolone withdrawal followed by human lymphoblastoid interferon on the treatment of chronic type B hepatitis in Asians: a randomized controlled trial. J Hepatol 1994 Feb; 20: 175-80
44. Castilla A. Civeira MP, Jáuregui JL, et al. Treatment of chronic hepatitis B with lymphoblastoid alpha interferon [in Spanish]. Med Clin 1989; 93 (16): 601-3
45. Fattovich G, Farci P, Rugge M, et al. A randomized controlled trial of lymphoblastoid interferon-alpha in patients with chronic hepatitiis-B lacking HBeAg. Hepatology 1992 Apr; 15: 584-9
46. Saracco G, Muzzella G, Rusina F, et al. A controlled trial of human lymphoblastoid imerferon in chronic hepatitis B in ltaly. Hepatology 1989; 10 (3): 336-41
47. Wong DKH, Yim C, Naylor CD, et al. Interferon alfa treatment of chronic hepatitis B: randomized tial in a predominantly homosexual male populalion. Gastroenterology 1995 Jan; 108: 165-71
48. Catterall AP, King R, Lau JYN, et al. Interferon-α therapy with and without interferon-α priming in patients with chronic hepatitis B infection. J Antimicrob Chemother 1993; 31 (5): 777-82
49. Fattovich G, Giustina G, Brollo L, et al. Therapy for chronic hepatitis B with lymphoblastoid interferon-α and levamisole. Hepatology 1992 Nov; 16: 1115-9
50. Janssen HLA, Berk L, Heijtink RA. Interferon-α and zidovudine combination therapy for chronic hepatitis B: results of a randomized. placebo-controlled trial. Hepatology 1993 Mar; 17: 383-8
51. Zavaglia C, Botelli R, Bellati G, et al. Treatment of chronic hepatitis B (HBeAg-HBV DNA-positive) with lymphoblastoid alpha interferon with or without corticosteroids: shortand long-term follow-up. Ital J Gastroenterol 1996; 28 (6): 324-31
52. Cianciara J, Gladysz A, Juszczyk J, et al. Randomized controlled trial of alpha-interferon (Wellferon) alone or following prednisone withdrawal in chronic hepatitis B - results of a multicenter, double blind study [in Polish]. Pol Arch Med Wewn 1992 Dec; 88: 430-40
53. Buti M, Jardi R, Rodriguez-Frias F. et al. Interferon vs. adenine arabinoside 5'-monophosphate in patients with anti-HBe-positive chronic hepatitis. J Med Virol 1996; 49 (4): 325-8
54. Wong DKH, Cheung AM, O'Rourke K, et al. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B: a meta-analysis. Ann Intern Med 1993; 119: 312-23
55. Korenman J, Baker B, Waggoner J, et al. Long-term remission of chronic hepatitis B after alpha-inteferon therapy. Ann Intern Med 1991; 114 (8): 629-34
56. Scullard GH, Smith CI, Merigan TC, et al. Effects of immunosuppressive therapy on viral markers in chronic active hepatitis B. Gastroenterology 1981; 81: 987-91
57. Sagnelli E, Manzillo G, Maio G, et al. Serum levels of hepatitis B surface and core antigens during immunosuppressive treatment of HBsAg-positive chronic active hepatitis. Lancet 1980 Aug 23; II: 395-7
58. Weller IVD, Bassendine MF, Murray A, et al. The effects of prednisolone/azathioprine in chronic hepatitis B viral infection, Gut 1982: 650-5
59. Cohard M, Poynard T, Mathurin P, et al. Prednisone-interferon combination in the treatment of chronic hepatitis B: direct and indirect metanalysis. Hepatology 1994 Dec; 20: 1390-8
60. Kuo G, Choo Q-L, Alter HJ, et al. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science 1989; 244: 362-4
61. Alter MJ, Hepatitis C: a sleeping giant? Am J Med 1991; 91 Suppl. 3B: 112-5S
62. Alter MJ. Epidemiology of hepatitis C. Hepatology 1997; 26 Suppl. 1: 62S-5S
63. Dienstag J. Sexual and perinatal transmission of hepatitis C. Hepatology 1997; 26 (3) Suppl. 1: 66S-70S
64. Lindsay KL. Therapy of hepatitis C: overview. Hepatology 1997: 26 Suppl. 1: 71S-7S
65. 1 interferon for 6 vs. 12 months. J Hepatol 1996 May; 24: 539-46
66. Camps J, Castilla A, Ruiz J, et al. Randomised trial of lymphoblastoid α-interferon in chronic hepatitis C. Effects on inflammation, fibrogenesis and viremia. J Hepatol 1993; 17 (3): 390-6
67. De Alava E, Camps J, Pardo-Mindan J. et al. Histological outcome of chronic hepatitis C treated with a 12-month course of lymphoblastoid alfa interferon. Liver 1993; 13 (2): 73-9
68. Rumi M, Del Ninno E, Parravicini ML, et al. A prospective, randoimized trial comparing lymphoblastoid to recombinant interferon alfa 2a as therapy for chronic hepatitis C. Hepatology 1996 Dec; 24: 1366-70
69. Tanaka K, Kondo M, Sakaguchi T, et al. Efficacy of ursodeoxycholic acid in combination with interferon-α in treating chronic hepatitis C: results of a long-term follow-up trial. J Gastroenterol Hepatol 1996 Dec: 11: 1155-60
70. Marcellin P, Hopf U, Tiepo C, et al. A randomised double-blind, controlled multicentre study of lymphoblastoid interferon alpha N1 in the treatment of adults wilh chronic hepatitis C. Glaxo Wellcome Inc. 1997 (Data on file)
71. Farrell GC, Bacon BR, Goldin RD, et al. Lymphoblastoid interferon-αn1 improves the long-term response to a six-month course of treatment in chronic hepatitis C compared with recomoinant interferon-α2b. Results of an international randomized controlled trial. Glaxo Wellcome Inc. 1997 (Data on file)
72. Kagawa T, Morizane T, Saito H, et al. A randomized, controlled trial of weekly administration of lymphoblastoid interferon in patients with chronic hepatitis C. J Hepatol 1997; 17 (I): 91-6
73. Tultavull TC. Baliellas C, Sese E, et al. Interferon may be useful in hemodialysis patients with hepatitis C virus chronic infection who are candidates for kidney transplant. Transplant Proc 1995; 27 (4): 2229-30
74. 1 and lymphoblastoid interferon treatment in chronic hepatitis C. Gut 1996 Nov; 39: 679-83
75. Kamowski B, Hofmann WJ, Otto HF, et al. Therapy of chronic hepatitis C and non-A, non-B with alpha -interferon [in German]. Inn Med 1991; 18 (4): 80-3
76. Tine F, Magrin S, Craxi A, et al. Interferon for non-A, non-B chronic hepatitis. A meta-analysis of randomised clinical trials. J Hepatol 1941; 13: 192-9
77. Bardelli F, Messori A, Rampazo R, et al. Effect of recombinant or lymphoblastoid interferon-α on alanine aminotransferase in patients with chronic hepatitis C or chronic non-A non-B hepatitis. Clin Drug Invest 1995; 9 (5): 239-54
78. Poynard T, Leroy V, Cohard M, et al. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology 1996; 24 (4): 77S-89
79. Bacon BR, Farrell G, Benhamou JP. Lymphoblastoid interferon improves long-term response to a six month course of treatment when compared with recombinant interferon alfa 2b: results of an international trial [abstract]. Hepatology 1995 Oct: 22 (Pt. 2): 152
80. Bellati G, Roffi L, Colloredo G, et al. Breakthrough and interferon dose in the therapy of chronic hepatitis C [abstract]. Hepatology 1996 Jan; 23: 1-41
81. Antonelli G, Giannelli G, Currenti M, et al. Fate of antibody to Interferon (IFN) in chronic hepatitis C patients treated with recombinant IFN alpha 2 and retreated with lymphoblastoid IFN alpha. Int Hepatol Commun 1995 Dec; 4: 232-7
82. Milella M, Antonelli G, Santantonio T, et al. Treatment with natural IFN of hepatitis C patients with or without antibodies to recombinant IFN. Hepatogastroenterology 1995; 42 (3): 201-4
83. Bellati G, Collnredo MG, Roffi L, et al. Prevalence of breakthrough during alpha interferon therapy for chronic hepatitis C [abstract]. Hepatology 1994 Oct; 20 (Pt 2): 331A
84. Colloredo G, Bellati G, Roffi L, et al. Prevalence of breakthrough in chronic hepatitis C during alpha interferon therapy [abstract]. J Gastroenterol Hepatol 1994 May-Jun; 9: A41
85. Bellati G, Colloredo G, Roffi L, et al. Prevalence of breakthrough in chronic hepatitis C patients undergoing antiviral therapy: role of type and schedule of alpha interferon. J Hepatol 1997 Feb; 26: 449-50
86. Roffi L, Colloredo Mels G, Antonelli G, et al. Breakthrough during recombinant interferon alfa therapy in patients with chronic hepatitis C virus infection: prevalence, etiology and management. Hepatology 1995; 21 Suppl. 3: 645-9
87. Cimino L, Citarella C, Nardone G, et al. Lymphoblastoid interferon in chronic hepatitis C patients, 'non-responders' to recombinant interferon-α (rIFN-α). J Hepatol 1992; 14 (2-3): 419-20
88. Ajello A, Freni MA, Spadaro A, et al. Lymphoblastoid interferon (IFN) in anti-HCV positive chronic hepatitis unaffected by other interferons [abstract]. J Hepatol 1993; 18 Suppl. 1: S87-8
89. Sachs F, Di Bisceglie AM, Dusheiko GM, et al. Treatment of hepatocellular carcinomas with recombinant leukocyte interferon: A pilot study. Br J Cancer 1985; 52: 105-9
90. Lyons SF, Schoub BD, Kew MC, et al. The use of interferon functional assays in the laboratory monitoring of patients with hepatocellular carcinoma receiving interferon. Am J Clin Pathol 1986; 85: 450-5
91. Saracco G, Rizzetto M. The long-term efficacy of interferon alfa in chronic hepatitis C palients: a critical review. J Gastroenterol Hepatol 1995 Nov-Dec; 10: 668-73
92. Camps J, Garcia-Grancro M, Riezu-Boj JI, et al. Prediction of sustained remission of chronic hepatitis C after a 12-month course of alfa interferon. J Hepatol 1994; 21 (1): 4-11
93. Martinot-Peignoux M, Marcellin P, Pouteau M, et al. Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C. Hepalology 1995; 22 (4): 1050-6
94. Hermida M, Castro A, Calvo SL, et al. HCV genotypes and viremia in predicting response to interferon alfa in chronic hepatitis C [abstract]. Hepatology 1995 Oct; 22 Pt 2: 428A
95. Davis GL, Lau JYN. Factors predictive of a beneficial response to therapy of hepatitis C. Hepatology 1997; 26 Suppl. 1: 122S-7S
96. Thomas HC, Scully LJ, McDonald JA. Lymphoblastoid and recombinant α-A interferon therapy of chronic hepatitis B virus infection. The Royal Free Hospital experience. J Hepatol 1986; 3 Suppl. (5) 2: S193-7
97. Hopf U, Berg T, König V, et al. Treatment of chronic hepatitis C with interferon alpha: long-term follow-up and prognostic relevance of HCV genotypes. J Hepatol 1996; 24 Suppl. 2: 67-73
98. Camps J, Crisóstomo S, García-Granero M, et al. Prediction of the response of chronic hepatitis C to interferon alfa: a statistical analysis of pretreatment variables. Gut 1993; 34 (12): 1714-7
99. Pugliaro L, Craxi A, Cammaa C. et al. Interferon- alpha for chronic hepatitis C: an analysis of pretreatment clinical predictors of response. Hepatology 1994; 19(4): 820-8
100. Fargion S, Fracanzani AL, Sampietro M. et al. Liver iron influ-ences the response to Interferon alpha therapy in chronic hepatitis C. Eur J Gastroenterol Hepatol 1997; 9: 497-503
101. Scully LJ, Brown D, Lloyd C et al. Immunological studies before and during Interferon therapy in chronic HBV infection: identification of factors predicting response. Hepalology 1990; 12 (5): 1111-7
102. Guadagnino V, Caroleo B, Izzi A, et al. T-lymphocyte subpopulations as factors predicting clinical response to interferon in hepatitis C virus-related chronic active hepatitis [2]. Infection 1995; 23(3): 189-90
103. Mazzella G, Salzetta A, Casanova S, et al. Treatment of chronic sporadic-type non-A. non-B hepatitis with lymphoblastoid Interferon: gamma GT levels predictive for response. Dig Dis Sci 1994; 39(4): 866-70
104. Yoshioka K, Yano M, Terazawa Y, et al. Randomized controlled trial of lymphoblastoid Interferon α for chrome hepatitis C (comparions of 6 MU versus 9 MU dosages): early disappearance of HCV RNA is essential for sustained response. American Association for the Study of Liver Diseases. Postgraduate Courses and 48th Annual Meeting. 1997 Nov 7-11; Chicago, 421A
105. Gil B, Qian C, Riezu-Boj JI, et al. Hepatic and extrahepatic HCV RNA strands in chronic hepatitis C: different patterns of response to interferon treatment. Hepatology 1993; 18 (5): 1050-4
106. Pardo M, Marriott E, Moliner MC, et al. Risks and benefits of interferon-α in the treatment of hepatitis. Drug Saf 1995 Nov; 13: 304-16
107. Marinho R, Serejo F, Raimundo M, et al. Adverse effects in hepatitis B and C treated with interferon. Any difference? [abstract]. Hepatology 1996 Oct; 24 Pt 2: Program Suppl: 543
108. Mazzella G, Villanova N, Abdu-Ahmed M, et al. Treatment of chronic hepatitis B with human lymphoblastoid interferon: results of a controlled trial [in English]. Chemioterapia 1988 Dec; 7 Suppl. 3: 12-4
109. Janssen HLA, Berk L, Schalm SW, et al. Antiviral effect of prolonged intermittent lymphoblastoid alpha interferon treatment in chronic hepatitis B. Gut 1992 Aug; 33: 1094-8
110. Haria M, Benfield P. Interferon-α-2a: a review of its pharmacological properties and therapeutic use in the management of viral hepatitis. Drugs 1995 Nov; 50: 873-96
111. Shakil AO, Di Bisceglic-AM, Hoofnagle JH. Seizures during alpha interferon therapy. J Hepatol 1996; 24 (1): 48-51
112. Di Cesare E, Previti M, Russo F, et al. Interferon-α therapy may induce insulin autoantibody development in patients with chronic viral hepatitis. Dig bis Sci 1996; 41 (8): 1672-7
113. Marcellin P, Pouteau M, Benhamou J-P. Hepatitis C virus infection. alpha interferon therapy and thyroid dysfunction. J Hepatol 1995 Mar; 22: 364-9
114. Lisker-Melman M, Di Bisceglie AM, Usala SJ, et al. Development of thyroid disease during therapy of chronic viral hepatitis with interferon alfa. Gastroenterology 1992; 102 (6): 2155-60
115. Custro N, Montalto G, Scafidi V, et al. Prospective study on thyroid autoimmunity and dysfunction related to chronic hepatitis C and interferon therapy. J Endocrinol Invest 1997; 20: 374-80
116. Sonnante AM, Cozzolongo R, Ragnini F, et al. Organ specific autoantibodies in patients with chronic hepatitis treated with Interferon (abstract). Gut 1995; 37 Suppl. 2: A234-235
117. Marazuela M, Garcia-Buey L, Gonzaiez-Fernandez B, et al. Thyroid autoimmune disorders in patients with chronic hepatitis C before and during interferon-α therapy. Clin Endocrinol 1996; 44 (6): 635-42
118. Perillo RP. Interferon in the management of chronic hepatitis B. Dig Dis Sci 1993; 38: 577-93
119. National Institutes of Health. National Institutes of Health Consensus Development Conference Panel Statement: management of hepatitis C. Hepatology 1997; 26 (3) Suppl. 1: 2S-10S
120. Schalm SW, Fattovich G, Brouwer JT. Therapy of hepatitis C: patients with cirrhosis. Hepatology 1997; 26 (3): 128S-32S
121. Alter MJ, Mast EE. The epidemiology of viral hepatitis in the United States. Gastroenterol Clin N Am 1994; 23: 437-55
122. Moradpour D, Wands JR. Understanding hepatitis B infection. N Engl J Med 1995; 332: 1092-3
123. McCarron B, Main J, Thomas HC. Viral hepatitis, new viruses and therapies. Curr Opin Infect Dis 1996 Oct; 9: 359-64
124. Di Bisceglie AM, Goodman ZD, Ishak KG, et al. Long-term clinical and histopathological follow-up of chronic posttransfusion hepatitis. Hepatology 1991; 14: 969-74
125. Tong MJ, El-Farra NS, et al. Clinical outocmes after transfusion-associated hepatitis. N Engl J Med 1995; 332: 1464-6
126. Alter HJ. Descartes before the horse: I clone, therefore I am: the hepatitis C virus in current perspective. Ann Intern Med 1991; 115: 644-9
127. Lemon SM, Thomas DL. Vaccines to prevent viral hepatitis. N Engl J Med 1997 Jan 16; 336: 196-203
128. Dusheiko GM, Khakoo S, Soni P, et al. A rational approach to the management of hepatitis C infection. BMJ 1996 Feb 10; 312: 357-64
129. Cantell K. Development of antiviral therapy with alpha interferons: promises, false hopes and accomplishments. Ann Med 1995 Feb; 27: 23-8
130. Saracco G, Rizzetto M. A practical guide to the use of interferons in the management of hepatitis virus infectious. Drugs 1997 Jan; 53: 74-85
131. Dusheiko GM. New treatments for chronic viral hepatitis B and C. Baillieres Clin Gastroenterol 1996 Jul; 10: 299-333
132. Böker KH, Ringe B, Krüger M, et al. Prostaglandin E plus lamciclovir - a new concept for the treatment of severe hepatitis B after liver transplantation. Transplantation 1994; 57: 1706-8
133. Doong S-L, Tsai C-H, Schinazi.RF, et al. Inhibition of the replication of hepatitis B virus in vitro by 2'3'-dideoxy-3'-thiacytidine and related analogues. Proc Natl Acad Sci U S A 1991; 88: 8495-9
134. Dienstag JL, Perrillo RP, Schiff HR, et al. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 1995; 133: 1657-61
135. Dienstag JL, Schilf ER, Gitlin N, et al. Extended lamivudine retreatment for chronic hepatitis B. Hepatology 1996; 24 Suppl. 188A
136. Kania RJ, Friedlander L, Van Thiel DH, et al. Lamivudine plus interferon for the treatment of IFN-nonresponsive chronic hepatitis C infection. American Association for the study of Liver Diseases; Postgraduate Courses and 48th Annual Meeting [abstract]: 1997 Nov 7-11; Chicago. 1626.
137. Thomas HC, Booth J, Brown J. Pathophysiology and treatment of hepatitis C. Drugs 1996; 52 Suppl. 2: 1-8
138. Alexopoulou A, Papakonstntinou A, Zafiropoulou E, et al. Randomised trial in HBeAg negative patients with replicating virus with lamivudine or ganciclovir in combination with interferon. Preliminary data. Hepatology 26 (Suppl.): Pt 2, Oct 1997
139. Blair CS, Haydon GH, Hayes PC. Current perspectives on the treatment and prevention of hepatitis C infection. Expert Opin Invest Drug 1996 Dec; 5: 1657-71
140. Colquhoun SD. Hepatitis C: a clinical update. Arch Surg 1996 Jan; 131: 18-23
141. Gregorio GV, Jara P, Hierro L, et al. Lymphoblastoid interferon alfa with of without steroid pretreatment in children with chronic hepatitis B: a multicenter controlled trial. Hepatology 1996 Apr; 23: 700-7
142. Giacchino R, Facco F, Giambartolomei G. et al. Treatment of children with chronic hepatitis B with a combination of steroids and human lymphoblastoid interferon. Chemioterapia 1988 Dec: 7 Suppl. 3: 20-5
143. Farci P, Karayiannis P, Brook MG, et al. Treatment of chronic hepatitis delta virus (HDV) infeclion with human lymphoblastoid alpha interferon. Q J Med 1989; 73 (271): 1045-54
144. Marzano A, Ottobrelli A, Spezia C, et al. Treatment of early chronic delta hepatitis with lymphoblastoid alpha interferon: A pilot study, Ital J Gastroenterol 1992; 24 (3): 119-21